Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT06572449
PHASE3

Study to Assess Safety and Effectiveness of Slowly Increasing Dose and Food Effect of KarXT in Participants With Schizophrenia

Sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company

View on ClinicalTrials.gov

Summary

The purpose of this study is to assess the safety and efficacy of slowly increasing dose and food effect of KarXT in adult participants with schizophrenia.

Official title: A Phase 3b, Open-label, Multicenter, Two-Period, Slow-titration and Food Effect Study to Assess the Safety and Efficacy of KarXT in Participants With DSM-5 Schizophrenia

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

173

Start Date

2024-10-28

Completion Date

2025-03-13

Last Updated

2026-06-22

Healthy Volunteers

No

Conditions

Interventions

DRUG

KarXT

Specified dose on specified days

Locations (6)

Local Institution - 0002

Los Alamitos, California, United States

Local Institution - 0004

Riverside, California, United States

Local Institution - 0006

Hollywood, Florida, United States

Local Institution - 0005

Atlanta, Georgia, United States

Local Institution - 0003

Decatur, Georgia, United States

Local Institution - 0001

Marlton, New Jersey, United States